Tecfidera (Dimethyl Fumarate) Denied by Insurance

Tecfidera (dimethyl fumarate) is an oral disease-modifying therapy developed by Biogen for adults with relapsing forms of multiple sclerosis, including relapsing-remitting MS (RRMS) and active secondary progressive MS. It works by activating the Nrf2 pathway, which has antioxidant and anti-inflammatory effects in the central nervous system. Tecfidera has been in use since its 2013 FDA approval and has a well-established safety and efficacy profile — making insurance denials particularly frustrating for the patients and neurologists who have relied on it for years.

Why Insurance Denies Tecfidera

Generic competition and formulary changes are now the most common source of Tecfidera denials. Following the entry of generic dimethyl fumarate (from Mylan and others) in 2021, many insurers moved brand-name Tecfidera off formulary or to a higher tier, instead covering only the generic equivalent. While generic dimethyl fumarate is bioequivalent, some patients and neurologists prefer the brand for reasons including formulation familiarity or specific excipient sensitivities. If your prescription is written for brand Tecfidera, it may be denied in favor of the generic unless a brand-medically-necessary exception is obtained.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization is still required for Tecfidera and its generic equivalents on many plans, particularly because MS medications are specialty drugs that require monitoring and documented diagnosis. PA criteria typically include: confirmed MS diagnosis, recent MRI confirming relapsing disease activity, neurologist certification, and sometimes documentation of baseline labs (lymphocyte count, liver function tests) required for Tecfidera safety monitoring.

Step therapy requirements can affect patients newly starting on Tecfidera. Some plans treat Tecfidera as a second-line agent, requiring trial of a first-line injectable (interferon beta or glatiramer acetate) before approving an oral DMT. This is particularly common in plans using older treatment algorithms that predate the widespread acceptance of oral DMTs as first-line options.

PML risk concerns arose following rare cases of progressive multifocal leukoencephalopathy (PML) associated with dimethyl fumarate, particularly in patients with prolonged severe lymphopenia. Some insurers have added monitoring requirements or warnings to their PA criteria that may complicate approval if a patient has had low lymphocyte counts on prior therapy.

How to Appeal a Tecfidera Denial

If the denial is formulary-based (brand vs. generic): Request a brand-medically-necessary exception if your physician has a clinical reason for prescribing brand Tecfidera over the generic. This might include documented adverse reactions to generic excipients or documented instability when previously switched. If no such clinical reason exists, accepting the generic may be the most practical path, as it provides the same active compound.

For prior authorization denials: Submit your most recent brain MRI report showing relapsing disease activity, your neurologist's documentation confirming your MS diagnosis and relapsing course, and baseline lab results (complete blood count with lymphocyte count, CMP for liver function) showing you are medically appropriate to start Tecfidera.

For step therapy denials: If your neurologist has determined that injectable first-line therapies are not appropriate for your case — due to needle phobia, injection site reactions, compliance concerns, or other factors — document this explicitly. An oral DMT may be preferable as first-line for patients who would not be adherent to weekly injections. Most step therapy override laws allow exceptions when the required first-line drug is inappropriate for the patient.

Lymphopenia considerations: If a prior insurer or physician has noted lymphopenia concerns, your appeal should include current lymphocyte counts and your neurologist's assessment that your counts are acceptable for starting or continuing Tecfidera. This directly addresses any safety-based denial language.

Cite AAN guidelines. The American Academy of Neurology and other neurology organizations support oral DMTs including dimethyl fumarate as appropriate first-line or second-line therapy for relapsing MS, and treatment decisions should be individualized based on patient preferences, comorbidities, and disease activity.

Patient Assistance Programs

Biogen offers Biogen Support Services, including copay assistance for commercially insured patients and a free drug program for qualifying uninsured or underinsured patients. Visit biogen.com/en-us/patient-support or call 1-800-456-2255.

Because generic dimethyl fumarate is now available, list prices have decreased substantially. However, specialty drug cost-sharing can still result in significant out-of-pocket costs even for generic versions, making copay support programs valuable.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?